Clinical trial
A Phase 2, Multicenter, Open-label Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06814145 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Open-label Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) With Heart Failure With Preserved Ejection Fraction (HFpEF)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 16, 2025
- Completion date
- August 10, 2035
- Enrollment
- 440 (estimated)
- Sites
- 57
Conditions
As the registry lists them; a condition with its own page is linked.